Mitral valve repair and mitral valve replacement are complementary methods considering early postoperative morbidity and mortality. Higher incidence of LCOS and in-hospital stay in the MVR + CABG group was to be expected on behalf of poorer preoperative status.
Out of all malignant tumors, metastatic melanoma has the highest propensity of heart metastases. Metastatic heart tumor is often a sign of disseminated malignant disease and poor prognosis. In our 39-year-old female patient, the symptoms of heart failure caused by metastatic melanoma of the right atrium were the first sign of advanced metastatic disease. The tumor masses were completely resected along with the affected wall of the right atrium, which was reconstructed with an autologous pericardial patch. The patient underwent further oncological treatment, and was asymptomatic for four years after surgery. Considering new treatment options in oncology a complete resection of metastatic heart melanoma offers a chance to improve quality of life and prognosis of these patients.
Introduction: Myxomas are the most common benign primary cardiac tumors with the majority (85%) located in the left atrium. Clinical manifestations are diverse and are consequence of embolic phenomena, intracardiac obstruction or constitutional symptoms. Early diagnosis, most perplexing in a patient with constitutional symptoms, remains an important challenge for the clinician, as they have an excellent prognosis following surgical excision, preventing complications and improving quality of life. 1-3Case report: We report a case of a 75-year-old female presented with fatigue and weight loss. Symptoms were first attributed to her history of hyperthyroidism. After series of normal hormonal and thyroid ultrasound findings she was referred to gastroenterologist for the evaluation of microcytic anemia (Hb 101g/L). Even though results of fecal occult blood testing were negative, esophagogastroduodenoscopy and colonoscopy were performed subsequently having sent our patient to hematologist for further examinations regarding anemia. After a year of anemia assessment she underwent transthoracic echocardiography which demonstrated an intraatrial mass. Immediately hospitalized, transesophageal echocardiography (Figure 1, Figure 2) and magnetic resonance imaging (Figure 3) were performed. Features of the mass were consistent with notably large myxoma, occupying nearly the entire left atrium and prolapsing across the mitral valve during diastole. Coronary angiography showed no obstructive coronary artery disease. Our patient underwent urgent cardiothoracic surgery with successful excision of atrial mass attached to the interatrial septum, pathologically confirmed myxoma (Figure 4). Cardiac rehabilitation followed immediately after discharge, with normalization of hemoglobin levels. Ivana Grgić CroEcho 2017Conclusion: Diagnosis of atrial myxomas is often challenging due to their asymptomatic nature or nonspecific symptoms presentation. Constitutional symptoms, like weight loss and fatigue and associated laboratory findings (elevated sedimentation rate and anemia) are explained as a result of interleukin-6 production by cardiac myxoma cells. Although histopathologically benign, complications due to their position and embolization can be fatal. Therefore, prompt complete surgical excision after diagnosis, regardless of whether the patient is symptomatic, is strongly recommended. The present case summons the significance of considering atrial myxoma while investigating a patient presenting with constitutional symptoms and persistent unexplained anemia. Early suspicion supported by echocardiogram may facilitate the diagnosis. Anemia: first manifestation of a left atrial myxoma
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.